Angelman Syndrome

Neurotherapeutics

Volumn 12, Issue 3, 2015, Pages 641-650

  Margolis, Seth S ^a   Sell, Gabrielle L ^a   Zbinden, Mark A ^a   Bird, Lynne M ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Angelman syndrome; autism; Imprinting; neurodevelopmental disorders; Ube3a; ubiquitin ligase

Indexed keywords

ANTICONVULSIVE AGENT; DNA; LEVODOPA; MINOCYCLINE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3A; UNCLASSIFIED DRUG; UBE3A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANTICONVULSANT THERAPY; AUTISM; CHROMOSOME 15Q; CHROMOSOME DELETION; CHROMOSOME MUTATION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DNA MARKER; DNA METHYLATION; FACILITATED COMMUNICATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENETIC ASSOCIATION; HAPPY PUPPET SYNDROME; HUMAN; MEDICAL RESEARCH; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; MOUSE MODEL; NEUROPATHOLOGY; NONHUMAN; PALLIATIVE THERAPY; POINT MUTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIGN LANGUAGE; UNIPARENTAL DISOMY; ANGELMAN SYNDROME; ANIMAL; AUTISM SPECTRUM DISORDER; BRAIN; DISEASE MODEL; FEMALE; GENETICS; MALE; METABOLISM; MOUSE; MUTATION; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGELMAN SYNDROME; ANIMALS; AUTISM SPECTRUM DISORDER; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MUTATION; NEURONS; UBIQUITIN-PROTEIN LIGASES;

EID: 84937410142     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0361-y     Document Type: Review

References (78)

1. Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 2006;140:413-418.
2. Bird LM. Angelman syndrome: review of clinical and molecular aspects. Appl Clin Genet 2014;7:93-104.
3. Dagli A, Buiting K, Williams CA. Molecular and clinical aspects of Angelman syndrome. Mol Syndromol 2012;2:100-112.
4. Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med 2010;12:385-395.
5. Williams CA. Looks like Angelman syndrome but isn’t—What is in the differential? RCPU Newsl 2011;22.
6. Tan WH, Bird LM, Thibert RL, Williams CA. If not Angelman, what is it? A review of Angelman-like syndromes. Am J Med Genet A 2014;164A:975-992.
7. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997;15:70-73.
8. Peters SU, Horowitz L, Barbieri-Welge R, Taylor JL, Hundley RJ. Longitudinal follow-up of autism spectrum features and sensory behaviors in Angelman syndrome by deletion class. J Child Psychol Psychiatry 2012;53:152-159.
9. Gentile JK, Tan WH, Horowitz LT, et al. A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations. J Dev Behav Pediatr 2010;31:592-601.
10. Tan WH, Bacino CA, Skinner SA, et al. Angelman syndrome: Mutations influence features in early childhood. Am J Med Genet A 2011;155A:81-90.
11. Valente KD, Varela MC, Koiffmann CP, et al. Angelman syndrome caused by deletion: a genotype-phenotype correlation determined by breakpoint. Epilepsy Res 2013;105:234-239.
12. Sahoo T, Peters SU, Madduri NS, et al. Microarray based comparative genomic hybridization testing in deletion bearing patients with Angelman syndrome: genotype–phenotype correlations. J Med Genet 2006;43:512-516.
13. Procter M, Chou LS, Tang W, Jama M, Mao R. Molecular diagnosis of Prader-Willi and Angelman syndromes by methylation-specific melting analysis and methylation-specific multiplex ligation-dependent probe amplification. Clin Chem 2006;52:1276-1283.
14. Albrecht U, Sutcliffe JS, Cattanach BM, et al. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 1997;17:75-78.
15. Nakao M, Sutcliffe JS, Durtschi B, Mutirangura A, Ledbetter DH, Beaudet AL. Imprinting analysis of three genes in the Prader-Willi/Angelman region: SNRPN, E6-associated protein, and PAR-2 (D15S225E). Hum Mol Genet 1994;3:309-315.
16. Rougeulle C, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. Nat Genet 1997;17:14-15.
17. Judson MC, Sosa-Pagan JO, Del Cid WA, Han JE, Philpot BD. Allelic specificity of Ube3a expression in the mouse brain during postnatal development. J Comp Neurol 2014;522:1874-1896.
18. Chamberlain SJ. RNAs of the human chromosome 15q11-q13 imprinted region. Wiley Interdiscip Rev RNA 2013;4:155-166.
19. Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci 2011;34:293-303.
20. Martins-Taylor K, Hsiao JS, Chen PF, et al. Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi syndrome patient with an atypical deletion. Hum Mol Genet 2014;23:2364-2373.
21. Meng L, Person RE, Huang W, Zhu PJ, Costa-Mattioli M, Beaudet AL. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model. PLoS Genet 2013;9:e1004039.
22. Mertz LG, Thaulov P, Trillingsgaard A, et al. Neurodevelopmental outcome in Angelman syndrome: genotype-phenotype correlations. Res Dev Disabil 2014;35:1742-1747.
23. Valente KD, Fridman C, Varela MC, et al. Angelman syndrome: uniparental paternal disomy 15 determines mild epilepsy, but has no influence on EEG patterns. Epilepsy Res 2005;67:163-168.
24. Nakatani J, Tamada K, Hatanaka F, et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 2009;137:1235-1246.
25. Smith SE, Zhou YD, Zhang G, Jin Z, Stoppel DC, Anderson MP. Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. Sci Transl Med 2011;3:103ra97.
26. Bhat S, Acharya UR, Adeli H, Bairy GM, Adeli A. Autism: cause factors, early diagnosis and therapies. Rev Neurosci 2014;25:841-850.
27. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001;2:943-955.
28. Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 2011;128:e488-e495.
29. Risch N, Hoffmann TJ, Anderson M, Croen LA, Grether JK, Windham GC. Familial recurrence of autism spectrum disorder: evaluating genetic and environmental contributions. Am J Psychiatry 2014;171:1206-1213.
30. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. The familial risk of autism. JAMA 2014;311:1770-1777.
31. Wood CL, Warnell F, Johnson M, et al. Evidence for ASD recurrence rates and reproductive stoppage from large UK ASD research family databases. Autism Res 2015;8:73-81.
32. Sutcliffe JS, Jiang YH, Galijaard RJ, et al. The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region. Genome Res 1997;7:368-377.
33. Cook EH, Jr., Lindgren V, Leventhal BL, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 1997;60:928-934.
34. Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009;459:569-573.
35. Jiang YH, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998;21:799-811.
36. Miura K, Kishino T, Li E, et al. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. Neurobiol Dis 2002;9:149-159.
37. Jiang YH, Pan Y, Zhu L, et al. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3. PLoS One 2010;5:e12278.
38. Huang HS, Burns AJ, Nonneman RJ, et al. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res 2013;243:79-90.
39. Heck DH, Zhao Y, Roy S, LeDoux MS, Reiter LT. Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors. Hum Mol Genet 2008;17:2181-2189.
40. Mulherkar SA, Jana NR. Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome. Neurobiol Dis 2010;40:586-592.
41. Piochon C, Kloth AD, Grasselli G, et al. Cerebellar plasticity and motor learning deficits in a copy-number variation mouse model of autism. Nat Commun 2014;5:5586.
42. van Woerden GM, Harris KD, Hojjati MR, et al. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci 2007;10:280-282.
43. Godavarthi SK, Dey P, Maheshwari M, Jana NR. Defective glucocorticoid hormone receptor signaling leads to increased stress and anxiety in a mouse model of Angelman syndrome. Hum Mol Genet 2012;21:1824-1834.
44. Riday TT, Dankoski EC, Krouse MC, et al. Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. J Clin Invest 2012;122:4544-4554.
45. Gustin RM, Bichell TJ, Bubser M, et al. Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis 2010;39:283-291.
46. Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 2006;1:122-124.
47. Yashiro K, Riday TT, Condon KH, et al. Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci 2009;12:777-783.
48. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 2008;17:111-118.
49. Kaphzan H, Hernandez P, Jung JI, et al. Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in Angelman syndrome model mice by ErbB inhibitors. Biol Psychiatry 2012;72:182-190.
50. Kaphzan H, Buffington SA, Ramaraj AB, et al. Genetic reduction of the alpha1 subunit of Na/K-ATPase corrects multiple hippocampal phenotypes in Angelman syndrome. Cell Rep 2013;4:405-412.
51. Wallace ML, Burette AC, Weinberg RJ, Philpot BD. Maternal loss of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific synaptic defects. Neuron 2012;74:793-800.
52. Martinez-Noel G, Galligan JT, Sowa ME, et al. Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes. Mol Cell Biol 2012;32:3095-3106.
53. Shirakura M, Murakami K, Ichimura T, et al. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol 2007;81:1174-1185.
54. Li L, Li Z, Howley PM, Sacks DB. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J Biol Chem 2006;281:1978-1985.
55. Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J Virol 2000;74:6408-6417.
56. Huang L, Kinnucan E, Wang G, et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999;286:1321-1326.
57. Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 1999;96:9557-9562.
58. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998;273:6439-6445.
59. Matentzoglu K, Scheffner M. Ubiquitin ligase E6-AP and its role in human disease. Biochem Soc Trans 2008;36:797-801.
60. Cooper EM, Hudson AW, Amos J, Wagstaff J, Howley PM. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem 2004;279:41208-41217.
61. Margolis SS, Salogiannis J, Lipton DM, et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 2010;143:442-455.
62. Greer PL, Hanayama R, Bloodgood BL, et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010;140:704-716.
63. Morrow EM, Yoo SY, Flavell SW, et al. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008;321:218-223.
64. Jensen L, Farook MF, Reiter LT. Proteomic profiling in Drosophila reveals potential Dube3a regulation of the actin cytoskeleton and neuronal homeostasis. PLoS One 2013;8:e61952.
65. Low HL, Chi-Fung JC Chi-Chen KC, Tew WL, Hew CSin, Ken-Shiung C. Angelman syndrome: proteomics analysis of an UBE3A knockout mouse and its implications. Available at:http://www.intechopen.com/books/advanced-topics-in-neurological-disorders/angelman-syndrome-proteomics-analysis-of-an-ube3a-knockout-mouse-and-its-implications. Accessed May 22, 2015.
66. Thibert RL, Larson AM, Hsieh DT, Raby AR, Thiele EA. Neurologic manifestations of Angelman syndrome. Pediatr Neurol 2013;48:271-279.
67. Thibert RL, Conant KD, Braun EK, et al. Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia 2009;50:2369-2376.
68. Bird LM, Tan WH, Bacino CA, et al. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet A 2011;155A:2956-2963.
69. Peters SU, Bird LM, Kimonis V, et al. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet A 2010;152A:1994-2001.
70. Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain 2004;127:1661-1669.
71. Brown AM, Deutch AY, Colbran RJ. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci 2005;22:247-256.
72. Harbord M. Levodopa responsive Parkinsonism in adults with Angelman Syndrome. J Clin Neurosci 2001;8:421-422.
73. Grieco JC, Ciarlone SL, Gieron-Korthals M, et al. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurol 2014;14:232.
74. Huang HS, Allen JA, Mabb AM, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012;481:185-189.
75. Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 2015;518:409-412.
76. King IF, Yandava CN, Mabb AM, et al. Topoisomerases facilitate transcription of long genes linked to autism. Nature 2013;501:58-62.
77. Powell WT, Coulson RL, Gonzales ML, et al. R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Proc Natl Acad Sci U S A 2013;110:13938-13943.
78. Mandel-Brehm C, Salogiannis J, Dhamne SC, Rotenberg A, Greenberg ME. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression. Proc Natl Acad Sci U S A 2015;112(16):5129-5134.